Zogenix (NASDAQ: ZGNX) and Senseonics Holdings (NASDAQ:SENS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitabiliy.
Profitability
This table compares Zogenix and Senseonics Holdings’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zogenix | -360.89% | -57.74% | -31.06% |
| Senseonics Holdings | -2,364.01% | N/A | -272.41% |
Institutional and Insider Ownership
87.1% of Zogenix shares are held by institutional investors. 5.0% of Zogenix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Zogenix and Senseonics Holdings’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| Zogenix | $22.34 million | 15.11 | -$68.12 million | ($3.26) | -4.17 |
| Senseonics Holdings | $884,999.00 | 256.25 | -$43.73 million | N/A | N/A |
Senseonics Holdings has higher revenue, but lower earnings than Zogenix.
Analyst Ratings
This is a summary of recent recommendations for Zogenix and Senseonics Holdings, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zogenix | 0 | 0 | 4 | 0 | 3.00 |
| Senseonics Holdings | 0 | 0 | 3 | 0 | 3.00 |
Zogenix currently has a consensus target price of $24.75, suggesting a potential upside of 81.99%. Senseonics Holdings has a consensus target price of $4.50, suggesting a potential upside of 86.72%. Given Senseonics Holdings’ higher probable upside, analysts clearly believe Senseonics Holdings is more favorable than Zogenix.
Summary
Zogenix beats Senseonics Holdings on 6 of the 10 factors compared between the two stocks.
About Zogenix
Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.
About Senseonics Holdings
Senseonics Holdings, Inc. is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes. The Company’s Eversense system consists of components, such as a sensor, which is inserted subcutaneously in the upper arm by a healthcare provider; an external removable smart transmitter that receives, assesses and relays the data from the sensor and also provides vibratory alerts, and a mobile application that receives data from the transmitter and provides real-time glucose readings, alerts and other data on the user’s mobile device, such as a smartphone, Apple Watch or tablet.
Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
